A Short Review on Important Drugs Under Clinical Trial Against COVID-19

Title:A Short Review on Important Drugs Under Clinical Trial Against COVID-19

Volume: 21 Issue: 13

Author(s): Namita Misra*

Affiliation:

• Resedential Area Apt. 4223, Indian Institute of Technology Jodhpur, Jodhpur 342037,India

Keywords: COVID-19, pneumonia, URI, WHO, SARS-CoV-2.

Abstract: Coronavirus spreads from one to another person, either by touching the hands or by touching the surface contaminated with this virus, and then touching the nose or mouth. COVID-19 infected human symptoms are like pneumonia symptoms, dry cough and high fever. Upper respiratory tract infections symptoms and sore throat are rare. It was first notified in China dated 12th December 2019 as a respiratory illness. In addition to travel restrictions and quarantine measures, everyone should follow the World Health Organization's advice guidelines on the management of humans infected with known or suspected infection with the SARS-CoV-2 virus at the personal level. The development of vaccine or medicines for the same is in progress and this short review will summarize the most potential candidates such as Remdesivir, Lopinavir and Ritonavir, Chloroquine, Hydroxychloroquine, Hydroxychloroquine with Azithromycin, Favipiravir, Umifenovir, and Ribavirin for its medicinal treatment.

Cite this article as:

Misra Namita *, A Short Review on Important Drugs Under Clinical Trial Against COVID-19, Mini-Reviews in Medicinal Chemistry 2021; 21 (13) . https://dx.doi.org/10.2174/1389557521666201217145333